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Background: Fluoroquinolones are among the most widely prescribed antibiotics. However, 
concerns about increasing resistant microorganisms and the risk of dysglycemia associated with 
the use of these agents have emerged. 
Objective: The primary objective of the study was to evaluate the appropriate use of com-
monly prescribed fluoroquinolones, including appropriate indication, dose, dose adjustment in 
renal impairment, and duration of treatment. The secondary objective was to investigate the 
dysglycemic effect of fluoroquinolone use (hypoglycemia and/or hyperglycemia) in diabetic 
and nondiabetic patients.
Methods: A prospective observational study at a teaching hospital in Lebanon was conducted 
over a 6-month period. A total of 118 patients receiving broad-spectrum fluoroquinolones 
(levofloxacin, ciprofloxacin, and moxifloxacin) were identified. Patients were mainly recruited 
from internal medicine floors and intensive care units.
Results: The final percentage for the appropriate indication, dose, and duration of fluoroqui-
nolone therapy was 93.2%, 74.6%, and 57.6%, respectively. A total of 57.1% of the patients 
did not receive the appropriate dose adjustment according to their level of renal impairment. In 
addition, dysglycemia occurred in both diabetic and nondiabetic patients. Dysglycemia was more 
frequently encountered with ciprofloxacin (50.0%), followed by levofloxacin (42.4%) and moxi-
floxacin (7.6%). Hyperglycemia was more common than hypoglycemia in all groups. The high-
est incidence of hyperglycemia occurred with levofloxacin (70.0%), followed by ciprofloxacin 
(39.0%) and moxifloxacin (33.3%). In contrast, hypoglycemia did not occur in the ciprofloxacin 
group, but it was more common with moxifloxacin (11.1%) and levofloxacin (6.0%).
Conclusion: The major clinical interventions for the future will adjust the dose and duration 
of therapy with commonly prescribed fluoroquinolones. The incidence of hypoglycemia was 
less common than hyperglycemia. 
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Introduction
Fluoroquinolones are one of the most commonly prescribed classes of antibiotics world-
wide.1 The development of newer generations of fluoroquinolones has expanded the 
traditional Gram-negative coverage to Gram-positive and anaerobic organisms.2 Fluoro-
quinolones are mainly used in the treatment of pneumonia and urinary tract infections.3
The increased use of fluoroquinolones has led to the emergence of recent concerns 
about resistance. The major factor is the inappropriate use of these agents in both com-
munity and hospital settings.4 In the Lebanese population, resistance to ciprofloxacin was 
estimated to be 40%–50% for Escherichia coli and Klebsiella spp. in 2013.5 Inappropri-
ate use of fluoroquinolones is linked to indication, dose, and duration of therapy.
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Additionally, concerns about the safety of fluoroquinolone 
antimicrobials have been addressed.6,7 Serious adverse events 
have led to the withdrawal of temafloxacin (because of hemoly-
sis, renal failure, and hypoglycemia),8,9 grepafloxacin and spar-
floxacin (because and QT prolongation),9,10 and trovafloxacin 
(because of hepatotoxicity).10,11 Furthermore, postmarketing 
surveillance of adverse events includes dysglycemia (hypogly-
cemia or hyperglycemia). On April 27, 2006, Bristol-Myers 
Squibb (New York, NY, USA) announced that it would stop 
manufacturing Tequin® (gatifloxacin), as the drug has been 
associated with potentially fatal blood glucose fluctuations.12
Both hypoglycemic and hyperglycemic episodes occur 
during therapy.13 Recent data show that fluoroquinolones 
can cause dysglycemia as an adverse effect in diabetic and 
nondiabetic patients.14 Although the exact mechanism of 
glucose homeostasis alteration is not fully known, animal 
studies suggest that fluoroquinolones can enhance insulin 
secretion by blocking adenosine triphosphate-sensitive K+ 
channels in pancreatic B-cells,15–18 leading to hypoglycemia. 
The hypoglycemic episodes have been mainly observed in 
patients receiving concomitant sulfonylurea antidiabetic 
agents.19 On the other hand, the mechanism of hyperglycemia 
is unclear. It may be due to a direct drug effect on glucose 
metabolism, or it may be a result of multiple confound-
ing factors.20 In addition, some recent findings imply that 
disturbed cellular glucose transport and GLUT1 function 
may underlie the dysglycemic effects of ciprofloxacin and 
levofloxacin.21 This adverse effect has important clinical 
implications, especially for diabetic patients.22
aim of the study
The primary objective of the study was to evaluate the 
appropriate use of commonly prescribed fluoroquinolones, 
including appropriate indication, dose, dose adjustment in 
renal impairment, and duration of treatment. The secondary 
objective was to investigate the dysglycemic effect of fluo-
roquinolone use in diabetic and nondiabetic patients.
ethical approval
The study was approved by the Hospital Institutional Review 
Board and informed consent was not required since there 
were no deviations from optimal medical practice. 
Methods
setting and design
A prospective study at a teaching hospital in Lebanon 
was conducted over a 6-month period. One hundred and 
eighteen patients receiving broad-spectrum fluoroquinolones 
(levofloxacin, ciprofloxacin, and moxifloxacin) were identified. 
Patients were mainly recruited from internal medicine floors 
and intensive care units. Patients were analyzed according to 
drug, indication, dose, and duration of therapy. 
sources of data
Electronic charts using the hospital database were identified, 
which included each patient’s chief complaint, past medical 
history, history of present illness, and all medications with 
their doses, routes of administration, and durations of therapy. 
Patients were followed up from initiation of fluoroquinolone 
use to the discharge date. A data collection form was used 
to evaluate the appropriate use of fluoroquinolones, which 
included patient demographic information, past medical his-
tory, the use of antidiabetic drugs, and pertinent laboratory 
tests (fasting blood glucose, hemoglucose test, and glycated 
hemoglobin [HbA
1C
], when available). The assessment was 
based on relevant guidelines from the Infectious Disease 
Society of America,23–28 manufacturer package inserts,29–31 
and clinical judgment. In addition, the relative risk of 
dysglycemia associated with fluoroquinolones among the 118 
hospitalized patients, as well as the impact of this important 
clinical outcome, will be reported.
Results
appropriateness of treatment
During the 6-month period, 118 hospitalized patients 
received fluoroquinolones (levofloxacin, ciprofloxacin, 
and moxifloxacin) for the treatment of their infections 
(Table 1). 
The characteristics of patients recruited in the study are 
shown in Table 2. Male sex was dominant (62.7%) with a 
mean age of 64 years versus 61 years for females. A total 
of 14.0% of the population were diabetic and 29.7% had 
renal impairment. Concomitant drug intake was evaluated, 
and baseline blood glucose was monitored in only 21.2% 
patients (Table 2). Around one-third of the patients (32.2%) 
Table 1 Summary of fluoroquinolone indications encountered 
in the study
Community-acquired pneumonia
Hospital-acquired pneumonia/ventilator-associated pneumonia
Chronic obstructive pulmonary disease exacerbation
Diabetic foot infection
skin and soft tissue infection
intra-abdominal infection
Urinary tract infection
Prophylaxis for transurethral resection of bladder tumor
Prophylaxis for endoscopic retrograde cholangiopancreatography
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were on concomitant steroid therapy for various indications 
and different durations of therapy.
Prior to starting antibiotic therapy, cultures were taken 
from different sites of infection: blood; urine; sputum; pus; 
bone; cerebrospinal fluid; and deep tracheal aspirate in 
70 patients (59.3%). Cultures were positive for bacterial 
microorganism(s) in 62.9% of the collected specimens. 
Gram-negative bacteria were the most commonly isolated 
microorganisms (Table 3).
indication
Ciprofloxacin
A total of 59 patients received ciprofloxacin. The most 
common indication for ciprofloxacin was diabetic foot 
infection (12 patients), followed by prophylaxis for transure-
thral resection of bladder tumor (eleven patients), urinary 
tract infections (ten patients), skin and soft tissue infec-
tions (six patients), prophylaxis for endoscopic retrograde 
cholangiopancreatography (five patients), intra-abdominal 
infections (three patients), community-acquired pneumonia 
(one patient), nosocomial pneumonia (one patient), and other 
types of infections (ten patients). The final results showed 
that 96.6% of the patients received ciprofloxacin for an 
appropriate indication (Table 4).
Levofloxacin
A total of 50 patients received levofloxacin. Most patients 
were treated with levofloxacin for community-acquired 
pneumonia (43 patients), followed by chronic obstructive pul-
monary disease exacerbations (five patients), intra-abdominal 
infections (one patient), and other types of infections (one 
patient). We observed that 94.0% of levofloxacin indications 
were appropriate (Table 4).
Moxifloxacin
Only nine patients received moxifloxacin. The two major 
indications for moxifloxacin were community-acquired 
pneumonia (three patients) and chronic obstructive pulmo-
nary disease exacerbations (two patients). In addition, one 
patient received moxifloxacin for the treatment of nosocomial 
pneumonia, one patient for the treatment of a urinary tract 
infection, and two patients for other types of infections. In 
the study, moxifloxacin was used for an appropriate indica-
tion in 66.7% of the patients (Table 4).
Dose 
In the levofloxacin and ciprofloxacin groups, 32 patients 
(64.0%) and 47 patients (79.7%) received the appropriate dose, 
respectively. All patients in the moxifloxacin group received 
Table 2 Baseline characteristics of the study population (n=118)
Characteristics Percentage
Demographic and medical characteristics
Female sex 37.3%
Male sex 62.7%
Mean female age 61 years
Mean male age 64 years
Renal impairment 29.7%
Diabetic 14.0%
nondiabetic 86.0%
Drug therapy
steroids 32.2%
insulin therapy 11.0%
Oral antidiabetic agents 5.1%
Combination
steroids + oral antidiabetic 4.2%
steroids + insulin 2.5%
steroids + insulin + oral antidiabetic 0.8%
Baseline blood glucose level*
normal 51.8%
hyperglycemia 47.1%
hypoglycemia 1.1%
Note: *Baseline blood glucose level was monitored in only 21.2% of the patients.
Abbreviation: n, total number.
Table 3 Microorganisms isolated in positive cultures during the 
study
gram-positive
Staphylococcus spp.
Streptococcus spp.
Enterococcus spp.
gram-negative
Pseudomonas spp.
Serratia spp.
Escherichia coli
Klebsiella spp.
extended spectrum beta-lactamase (E. coli, Klebsiella spp.)
Proteus spp.
Acinetobacter spp.
Citrobacter spp.
Morganella spp.
Alcaligenes xylosoxidans
anaerobes
Candida spp.
Table 4 Summary of the results of fluoroquinolone indications
Fluoroquinolone Indication
Appropriate Inappropriate 
Ciprofloxacin 96.6% 3.4%
Levofloxacin 94.0% 6.0%
Moxifloxacin 66.7% 33.3%
Weighted average percentage 93.2% 6.8%
Note: The final weighted average percentage of the appropriate indication for fluor-
oquinolones is 93.2%.
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the correct dose (Tables 5 and 6). The appropriate doses per 
indication are mentioned in the Supplementary materials.
Dose adjustment in renal impairment
In the study, renal impairment that required a dosage 
adjustment for levofloxacin and ciprofloxacin was defined as 
a creatinine clearance 50 mL/minute. Moxifloxacin does 
not require dosage adjustment in kidney dysfunction. Out 
of 118 patients, 35 patients had renal impairment. A total of 
12 and eight patients in the levofloxacin and ciprofloxacin 
groups, respectively, did not receive the correct dosage 
adjustment according to their level of renal impairment. Two 
patients on hemodialysis and one patient with a creatinine 
clearance of 32.7 mL/minute were treated with moxifloxacin 
(Table 7).
Duration
In the levofloxacin, ciprofloxacin, and moxifloxacin groups, 
30 patients (60.0%), 31 patients (52.5%), and seven patients 
(77.8%) received the appropriate duration of therapy, respec-
tively (Table 8).
Dysglycemia
In the study, we defined hyperglycemia when glucose 
levels were 150 mg/dL and hypoglycemia when they 
were 70 mg/dL. To evaluate the relative risk of dysglyce-
mia associated with fluoroquinolone use, we grouped patients 
into one of two groups: diabetics and nondiabetics. The 
majority of the population in the study were nondiabetic; the 
incidence of dysglycemia with ciprofloxacin, levofloxacin, 
and moxifloxacin in diabetic and nondiabetic patients is 
reported in Table 9. Dysglycemia occurred more frequently 
with ciprofloxacin (50.0%), followed by levofloxacin 
(42.4%) and moxifloxacin (7.6%) (Table 9).
Blood glucose monitoring
Blood glucose was monitored using pertinent laboratory 
tests such as fasting blood glucose, hemoglucose test, and 
HbA
1C
 in 49.2%, 90.0%, and 77.8% of patients in the cipro-
floxacin, levofloxacin, and moxifloxacin groups, respectively 
(Table 10). Baseline blood glucose was monitored in 21.2% of 
the patients and they were classified according to normal blood 
glucose levels, hypoglycemia, or hyperglycemia (Table 10).
Table 5 Fluoroquinolone doses in different indications
Fluoroquinolone Dose
Appropriate (n) Inappropriate (n)
Ciprofloxacin
CaP 1 0
HAP/VAP 1 0
Diabetic foot infection 10 2
ssTi 5 1
Prophylaxis for TURBT 10 1
Prophylaxis for eRCP 5 0
iai 3 0
UTi 2 8
Others 10 0
Levofloxacin
CaP 28 15
COPD exacerbation 4 1
iai 0 1
Others 0 1
Moxifloxacin
CaP 3 0
HAP/VAP 1 0
COPD exacerbation 2 0
UTi 1 0
Others 2 0
Abbreviations: n, number of patients; CAP, community-acquired pneumonia; 
COPD, chronic obstructive pulmonary disease; HAP, hospital-acquired pneumonia; 
VAP, ventilator-associated pneumonia; SSTI, skin and soft tissue infection; TURBT, 
transurethral resection of bladder tumor; eRCP, endoscopic retrograde cholangio-
pancreatography; UTi, urinary tract infection; iai, intra-abdominal infection.
Table 6 Summary of the doses of fluoroquinolone therapy
Fluoroquinolone Dose
Appropriate Inappropriate
Ciprofloxacin 79.7% 20.3%
Levofloxacin 64.0% 36.0%
Moxifloxacin 100.0% 0.0%
Weighted average percentage 74.6% 25.4%
Note: The final weighted average percentage of the appropriate dose of fluoro qui-
nolones is 74.6%.
Table 7 summary of patients with renal impairment
Fluoroquinolone Number of patients  
with renal impairment
Inappropriate dose 
adjustment (%)
Ciprofloxacin 18 44.4
Levofloxacin 14 85.7
Moxifloxacin 3 no need for dose  
adjustment
Table 8 Summary of the duration of fluoroquinolone therapy
Fluoroquinolone Duration
Appropriate Inappropriate 
Ciprofloxacin 52.5% 47.5%
Levofloxacin 60.0% 40.0%
Moxifloxacin 77.8% 22.2%
Weighted average percentage 57.6% 42.4%
Note: The final weighted average percentage of the appropriate duration of fluoro-
quinolone therapy is 57.6%.
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number of episodes
Hyperglycemia was more common than hypoglycemia in all 
groups. The highest incidence of hyperglycemia occurred 
with levofloxacin in 70.0% of the cases, followed by 39.0% 
with ciprofloxacin, and 33.3% with moxifloxacin. In contrast, 
hypoglycemia did not occur in the ciprofloxacin group, but 
it was more common with moxifloxacin (11.1%), followed 
by levofloxacin (6.0%) (Table 11).
Concomitant medications
A total of 47 patients were taking additional medications that 
can affect blood glucose levels concomitantly with their fluo-
roquinolone therapy. These medications included steroids, 
insulin regimens, and/or oral anti-diabetic agents.
Discussion
In Lebanon, concerns about microorganisms resistant to 
fluoroquinolones have emerged in both community and 
hospital settings.4 No large-scale studies have examined the 
inappropriate use of these agents and their impact on the 
Lebanese population. In our prospective observational study, 
we found that commonly prescribed fluoroquinolones were 
used according to the appropriate indication in 93.2% of the 
patients. This finding shows that fluoroquinolones are being 
prescribed appropriately in a hospital setting. However, dos-
ing of these agents was adequate in only 74.6% of the patients 
and 57.2% did not receive the correct dose adjustment based 
on their level of renal impairment. In addition, only 57.6% 
of the patients received the appropriate duration of treat-
ment. Based on the results of this study, the major clinical 
interventions for the future will involve adjusting the dose 
and duration of fluoroquinolones. Clinical pharmacists can 
have a great impact on decreasing the widespread resistance 
by reviewing and promoting rational antibiotic therapy. Thus, 
pharmacists in collaboration with other health care profes-
sionals can contribute to provide optimal patient care and 
appropriate drug use. 
A major issue before the initiation of antimicrobial 
agents is to take cultures in all patients whenever possible. 
In our study, cultures were only taken from 59.3% of the 
patients. Clinical pharmacists can play a tremendous role in 
de-escalating treatment when indicated and in sparing the 
use of broad-spectrum fluoroquinolones.
Dysglycemic events were not restricted to diabetic 
patients. The glycemic control issue with fluoroquinolones 
became a concern in 2006 when Bristol-Myers Squibb 
stopped manufacturing Tequin® (gatifloxacin).12 Although 
most of the effects on glucose homeostasis have been linked 
to gatifloxacin, it should be noted that all fluoroquinolones 
can cause blood glucose fluctuations.20,32,33 Baseline blood 
glucose levels before the initiation of fluoroquinolones were 
checked only in 21.2% of the patients and 27.7% did not have 
their blood glucose monitored during therapy.
There is a growing body of literature documenting 
the increased complication rates of high blood glucose 
levels.32,33 Additionally, the literature documents the positive 
effect of tightly controlled glucose in various disease states, 
especially infections.32,33 Therefore, based on the institution 
sliding scale of insulin, we defined hyperglycemia when glu-
cose levels exceeded 150 mg/dL. Compared to other studies, 
this level is relatively stricter. Interestingly, hyperglycemia 
occurred frequently with levofloxacin (70.0%), followed by 
ciprofloxacin (39.0%) and moxifloxacin (33.3%). Several 
confounding factors may have contributed to these find-
ings. For example, the presence of stress factors and other 
disease state interactions may have increased blood glucose 
levels. In addition, 32.2% of the patients were taking steroids 
concomitantly with their fluoroquinolone therapy. This was 
a confounding factor in our study because the administra-
tion of a steroid can cause hyperglycemia due to a decrease 
in both insulin secretion and insulin sensitivity. Another 
confounding factor that could have affected the results was 
Table 9 incidence of dysglycemia in diabetic and nondiabetic 
patients
Fluoroquinolone Patients developing 
dysglycemia
Diabetics
Yes No
Ciprofloxacin 50.0% 28.8% 71.2%
Levofloxacin 42.4% 24.0% 76.0%
Moxifloxacin 7.6% 33.3% 66.7%
Table 10 Blood glucose level monitoring
Fluoroquinolone Glucose monitoring Baseline
Yes No Yes No
Normal Hyperglycemia Hypoglycemia
Ciprofloxacin 49.2% 50.8% 13.6% 22.0% 1.7% 62.7%
Levofloxacin 90.0% 10.0% 16.0% 14.0% 0.0% 70.0%
Moxifloxacin 77.8% 22.2% 22.2% 11.1% 0.0% 66.7%
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that the baseline blood glucose levels were checked in only 
21.2% of the patients; thus, a correlation between baseline 
and subsequently measured glucose concentrations was dif-
ficult to interpret.
On the other hand, the incidence of hypoglycemia was 
less common than hyperglycemia. Hypoglycemia was 
defined as blood glucose levels 70 mg/dL. In this study, 
11.1% and 6.0% of the patients had hypoglycemic episodes 
in the moxifloxacin and levofloxacin groups, respectively, 
and none in the ciprofloxacin group. In this study, concomi-
tant hypoglycemic drug treatment was the major interacting 
factor. For example, 11.0% and 5.1% of patients were taking 
insulin and oral antidiabetic drugs, respectively. In a case 
control study of 7,287 patients who received gatifloxacin or 
levofloxacin, 1.6% recorded a glucose level 51 mg/dL.34 
This life-threatening side effect, which is often masked by the 
underlying disease, must be carefully monitored especially 
when fluoroquinolones are used.
Although our study was prospective in nature, it has 
several limitations. It was designed to be observational, 
which limits the pharmacist’s interventions. In addition, the 
survival rate was not followed up and the pharmacists were 
not in direct contact with the patients.
Conclusion
Overall, our findings provided important implications for 
clinical practice. Major clinical interventions for the future 
will include adjusting the dose and duration of therapy 
with fluoroquinolones. The incidence of hypoglycemia 
with commonly prescribed fluoroquinolones was less than 
hyperglycemia. Underestimating the potential risk of 
dysglycemia associated with fluoroquinolone use may 
lead to serious complications in diabetic and nondiabetic 
patients.
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Table S1 Ciprofloxacin oral dosage
Ciprofloxacin
(FDA-approved indication)
Severity PO dose  
(adult)
Frequency Duration
UTi acute uncomplicated 250 mg q 12 h 3 days
Mild/moderate 250 mg q 12 h 7–14 days
Severe/complicated 500 mg q 12 h 7–14 days
Chronic prostatitis Mild/moderate 500 mg q 12 h 28 days
acute sinusitis Mild/moderate 500 mg q 12 h 10 days
lower RTi Mild/moderate 500 mg q 12 h 7–14 days
Severe/complicated 750 mg q 12 h 7–14 days
ssTi Mild/moderate 500 mg q 12 h 7–14 days
Severe/complicated 750 mg q 12 h 7–14 days
Bone and joints Mild/moderate 500 mg q 12 h 4–6 weeks
Severe/complicated 750 mg q 12 h 4–6 weeks
infectious diarrhea Mild/moderate/severe 500 mg q 12 h 5–7 days
Typhoid fever Mild/moderate 500 mg q 12 h 10 days
intra-abdominal Complicated 500 mg q 12 h 7–14 days
Neisseria gonorrhoeae Uncomplicated 250 mg single dose single dose
Notes: Ciprofloxacin should be used as 400 mg IV q 8 h or 750 mg PO q 12 h for febrile neutropenia and nosocomial pneumonia for patients with normal kidney function.
Abbreviations: FDA, United States Food and Drug Administration; PO, per os; UTI, urinary tract infection; q 12 h, every 12 hours; RTI, respiratory tract infection; 
SSTI, skin and soft tissue infection; IV, intravenous; q 8 h, every 8 hours.
Table S2 Ciprofloxacin equivalent AUC dosing regimen
Ciprofloxacin  
oral dosage
Equivalent ciprofloxacin IV 
dosage
250 mg tablet q 12 h 200 mg IV q 12 h
500 mg tablet q 12 h 400 mg IV q 12 h
750 mg tablet q 12 h 400 mg IV q 8 h
Abbreviations: AUC, area under the curve; IV, intravenous; q 12 h, every 
12 hours; q 8 h, every 8 hours.
Table S3 Adjustment of ciprofloxacin dose in renal impairment
CrCl 25–49 mL/minute 200–400 mg IV q 12 h
250–500 mg PO q 12 h
CrCl 25 mL/minute 200 mg IV q 12 h
250–500 mg PO q 24 h
hemodialysis 250–500 mg PO q 24 h (after dialysis)
Abbreviations: CrCl, creatinine clearance; IV, intravenous; q 12 h, every 12 hours; 
PO, per os; q 24 h, every 24 hours.
Table S4 Levofloxacin oral/IV dosage
Levofloxacin (FDA-
approved indication)
PO/IV dose  
(adult)
Frequency Duration
aeCB 500 mg q 24 h 7 days
750 mg q 24 h 5 days
CaP 500 mg q 24 h 7–14 days
750 mg q 24 h 5 days
sinusitis 500 mg q 24 h 10–14 days
750 mg q 24 h 5 days
haP 750 mg q 24 h 7–14 days
Uncomplicated ssTi 500 mg q 24 h 7–10 days
Complicated ssTi 750 mg q 24 h 7–14 days
Chronic prostatitis 500 mg q 24 h 28 days
Complicated UTi 250 mg q 24 h 10 days
750 mg q 24 h 5 days
acute pyelonephritis 250 mg q 24 h 10 days
750 mg q 24 h 5 days
Uncomplicated UTi 250 mg q 24 h 3 days
Abbreviations: FDa, United states Food and Drug administration; PO, per os; 
IV, intravenous; AECB, acute exacerbations of chronic bronchitis; q 24 h, every 
24 hours; CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; 
ssTi, skin and soft tissue infection; UTi, urinary tract infection.
Table S5 Adjustment of levofloxacin dose in renal impairment
Acute sinusitis, AECB, CAP, uncomplicated SSTI, chronic 
bacterial prostatitis
CrCl 50 mL/minute No dosage adjustment required
CrCl 20–49 mL/minute 500 mg then 250 mg q 24 h
CrCl 10–19 mL/minute 500 mg then 250 mg q 48 h
hemodialysis 500 mg then 250 mg q 48 h
Complicated SSTI, nosocomial pneumonia
CrCl 20–49 mL/minute 750 mg q 48 h
CrCl 10–19 mL/minute 500 mg q 48 h
Abbreviations: aeCB, acute exacerbations of chronic bronchitis; CaP, community-
acquired pneumonia; SSTI, skin and soft tissue infection; CrCl, creatinine clearance; 
q 24 h, every 24 hours; q 48 h, every 48 hours.
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Table S6 Moxifloxacin oral/IV dosage
Moxifloxacin
(FDA-approved indication)
PO/IV dose 
(adult)
Frequency Duration
acute bacterial sinusitis 400 mg q 24 h 10 days
aeCB 400 mg q 24 h 5 days
CaP 400 mg q 24 h 10 days
Uncomplicated ssTi 400 mg q 24 h 7 days
Complicated ssTi 400 mg q 24 h 7–21 days
Complicated intra-abdominal infections 400 mg q 24 h 5–14 days
Abbreviations: FDA, United States Food and Drug Administration; AECB, acute exacerbations of chronic bronchitis; CAP, community-acquired pneumonia; SSTI, skin and 
soft tissue infection; q 24 h, every 24 hours.
